Genes in panel
Regions in panel
Prev Next

Mendeliome

Gene: SAMD9

Green List (high evidence)

SAMD9 (sterile alpha motif domain containing 9)
EnsemblGeneIds (GRCh38): ENSG00000205413
EnsemblGeneIds (GRCh37): ENSG00000205413
OMIM: 610456, Gene2Phenotype
SAMD9 is in 12 panels

2 reviews

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Green List (high evidence)

The association between mono-allelic variants and disease is well established. Developmental delay is a feature of MIRAGE syndrome.

Bi-allelic variants: in effect only two families reported (founder variant in 5 Jewish Yemenite families, plus one other). Amber for this association.
Created: 21 Mar 2022, 7:16 a.m. | Last Modified: 21 Mar 2022, 7:16 a.m.
Panel Version: 0.11687

Mode of inheritance
BOTH monoallelic and biallelic, autosomal or pseudoautosomal

Phenotypes
MIRAGE syndrome, MIM#617053; Tumoral calcinosis, familial, normophosphatemic, MIM#610455; Monosomy 7 myelodysplasia and leukemia syndrome 2, MIM# 619041

Samantha Ayres (Victorian Clinical Genetics Services)

Green List (high evidence)

Gain of function listed as disease mechanism in regard to MIRAGE syndrome (AD).
I note that SAMD9 is listed as a green gene on MM gene list (AR)- however there is a review questioning whether there is enough evidence for the AR tumoral calcinosis - based on few cases and only two published variants? These variants are noted to be LOF.
SAMD9 is also included on the ID gene list with no review. I have not come across an association with ID or learning concerns - ? remove from ID gene list
Created: 21 Mar 2022, 2:19 a.m. | Last Modified: 21 Mar 2022, 2:19 a.m.
Panel Version: 0.11659

Mode of inheritance
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted

Phenotypes
MIRAGE syndrome, MIM#617053; Tumoral calcinosis, familial, normophosphatemic, MIM#610455; Monosomy 7 myelodysplasia and leukemia syndrome 2, MIM#619041

Publications

Details

Mode of Inheritance
BOTH monoallelic and biallelic, autosomal or pseudoautosomal
Sources
  • Expert Review Green
  • Victorian Clinical Genetics Services
Phenotypes
  • MIRAGE syndrome, MIM#617053
  • Tumoral calcinosis, familial, normophosphatemic, MIM#610455
  • Monosomy 7 myelodysplasia and leukemia syndrome 2, MIM# 619041
OMIM
610456
Clinvar variants
Variants in SAMD9
Penetrance
None
Publications
Panels with this gene

History Filter Activity

21 Mar 2022, Gel status: 3

Entity classified by Genomics England curator

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Gene: samd9 has been classified as Green List (High Evidence).

21 Mar 2022, Gel status: 3

Set Phenotypes

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Phenotypes for gene: SAMD9 were changed from to MIRAGE syndrome, MIM#617053; Tumoral calcinosis, familial, normophosphatemic, MIM#610455; Monosomy 7 myelodysplasia and leukemia syndrome 2, MIM# 619041

21 Mar 2022, Gel status: 3

Set publications

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Publications for gene: SAMD9 were set to

21 Mar 2022, Gel status: 3

Set mode of inheritance

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Mode of inheritance for gene: SAMD9 was changed from Unknown to BOTH monoallelic and biallelic, autosomal or pseudoautosomal

17 Nov 2019, Gel status: 3

Created, Added New Source, Set mode of inheritance

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

gene: SAMD9 was added gene: SAMD9 was added to Mendeliome_VCGS. Sources: Expert Review Green,Victorian Clinical Genetics Services Mode of inheritance for gene: SAMD9 was set to Unknown